Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease

Journal of Gastrointestinal and Liver Diseases

Volumn 25, Issue 2, 2016, Pages 159-165

  Fialho, Andrea ^a   Fialho, Andre ^a   Thota, Prashanthi ^a   McCullough, Arthur J ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Metabolic syndrome; Non alcoholic fatty liver disease; Small intestinal bacterial overgrowth

Indexed keywords

GLUCOSE; HYDROGEN; METHANE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL OVERGROWTH; BREATH ANALYSIS; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; FATTY LIVER; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; SMALL INTESTINE; BACTERIUM; CHI SQUARE DISTRIBUTION; DIAGNOSTIC IMAGING; ELECTRONIC HEALTH RECORD; GROWTH, DEVELOPMENT AND AGING; INTESTINE FLORA; MICROBIOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; RETROSPECTIVE STUDY; STATISTICAL MODEL; X-RAY COMPUTED TOMOGRAPHY;

BACTERIA; BREATH TESTS; CHI-SQUARE DISTRIBUTION; ELECTRONIC HEALTH RECORDS; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINE, SMALL; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84969988108     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395. doi: 10.1002/hep.20466
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52. doi: 10.1002/hep.20734
3. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-15723. doi: 10.1073/pnas.0407076101
4. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484. doi: 10.1038/ nature07540
5. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60. doi: 10.1038/ nature11450
6. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103. doi: 10.1038/nature12198
7. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772. doi: 10.2337/db06-1491
8. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740-E747. doi: 10.1152/ajpendo.00302.2006
9. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol 2014; 20: 16079-16094. doi: 10.3748/wjg.v20.i43.16079
10. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006; 103: 12511-12516. doi: 10.1073/pnas.0601056103
11. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609. doi: 10.1002/hep.26093
12. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185. doi: 10.1038/nature10809
13. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991; 100: 513-519.
14. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol 2008; 14: 313-317. doi: 10.3748/wjg.14.313
15. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211. doi: 10.1136/gut.48.2.206
16. Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007; 13: 6016-6021.
17. Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995; 16: 16-33.
18. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7: 846-858. doi: 10.4254/wjh.v7.i6.846
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
20. Shanab AA, Scully P, Crosbie O, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56: 1524-1534. doi: 10.1007/s10620-010-1447-3
21. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007; 17: 1374-1380. doi: 10.1007/ s11695-007-9243-7
22. Sabaté JM, Jouët P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008; 18: 371-377. doi: 10.1007/ s11695-007-9398-2
23. Kapil S, Duseja A, Sharma BK, et al. Small intestinal bacterial overgrowth and toll like receptor signaling in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31: 213-221. doi: 10.1111/ jgh.13058
24. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11. doi: 10.1172/JCI11830
25. Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415-424. doi: 10.1136/gut.2005.071118
26. Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur J Gastroenterol Hepatol 2008; 20: 995-1001. doi: 10.1097/MEG.0b013e3282fdf65f
27. Soza A, Riquelme A, González R, et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50: 1136-1140. doi: 10.1007/s10620-005-2720-8
28. Fan JG, Xu ZJ, Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol 2005; 11: 5053-5056. doi: 10.3748/wjg.v11.i32.5053
29. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011; 140: 976-986. doi: 10.1053/j.gastro.2010.11.049
30. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023. doi: 10.1038/4441022a
31. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031. doi: 10.1038/nature05414
32. Bruel L, Sulzenbacher G, Cervera Tison M, et al. α-Galactosidase/ sucrose kinase (AgaSK), a novel bifunctional enzyme from the human microbiome coupling galactosidase and kinase activities. J Biol Chem 2011; 286: 40814-40823. doi: 10.1074/jbc.M111.286039
33. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013; 56: 461-468. doi: 10.1097/ MPG.0b013e318284abb5
34. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341: 1241214. doi: 10.1126/science.1241214
35. Lassenius MI, Pietiläinen KH, Kaartinen K, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34: 1809-1815. doi: 10.2337/dc10-2197
36. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-951. doi: 10.1002/hep.25772
37. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-924. doi: 10.1002/hep.23784
38. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262-265. doi: 10.1016/S1542-3565(04)00014-X
39. Riley TR 3rd, Mendoza A, Bruno MA. Bedside ultrasound can predict nonalcoholic fatty liver disease in the hands of clinicians using a prototype image. Dig Dis Sci 2006; 51: 982-985. doi: 10.1007/s10620-006-9343-6
40. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008; 28: 386-395. doi: 10.1055/s-0028-1091983
41. Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015; 27: 481-489. doi: 10.1111/ nmo.12516
42. Rezaie A, Pimentel M, Rao SS. How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. Curr Gastroenterol Rep 2016; 18: 8. doi: 10.1007/s11894-015-0482-9